Atrandi Biosciences Unveils Single-Cell Direct Multiomics Tech at SLAS 2026

New Semi-Permeable Capsule platform enables flexible, high-throughput single-cell analysis workflows.

Published on Feb. 6, 2026

Got story updates? Submit your updates here. ›

Atrandi Biosciences, a life sciences tools company, announced it will present its patented Semi-Permeable Capsule (SPC) technology at the SLAS2026 International Conference and Exhibition in Boston. The SPC platform offers multi-step processing at single-cell resolution, allowing researchers to stage complex workflows while preserving cell identity. Atrandi will also showcase its Phyx AI-driven screening and enrichment platform, which works in tandem with the SPC technology.

Why it matters

Atrandi's innovations aim to address longstanding challenges in single-cell analysis workflows, enabling more flexible, high-throughput experiments that can handle complex, multi-step processes without losing critical data on individual cells. This could unlock new opportunities in areas like CRISPR screens, rare clone tracking in cancer, and microbial single-cell genomics.

The details

Atrandi's SPC technology combines the flexibility of well-based assays with the high throughput of droplet microfluidics, allowing bulk-like reactions at single-cell resolution. Researchers can exchange reagents, stage sequential reactions, and preserve each cell's identity throughout complex workflows. The company's Phyx platform then enables AI-driven screening and enrichment, so labs can focus downstream analysis only on the most biologically relevant cells.

  • The SLAS2026 International Conference and Exhibition will take place from February 7-11, 2026 in Boston.
  • Atrandi will present a featured podium presentation on February 9 from 11:30 am to 11:55 am in Room 204AB.
  • Atrandi will also present a featured scientific poster on February 10 from 2:00 pm to 3:00 pm in Exhibit Hall AB.

The players

Atrandi Biosciences

A life sciences tools company advancing single-cell analysis technologies.

Emilis Gegevičius

A representative from Atrandi Biosciences who commented on the company's SPC technology.

Got photos? Submit your photos here. ›

What they’re saying

“Atrandi SPCs turn single-cell analysis into a true multi-step workflow. You can exchange reagents, stage sequential reactions, and keep each cell's identity intact, so studies like CRISPR perturbation screens including Perturb-seq, rare clone tracking in cancer, and complex microbial single-cell genomics don't collapse under workflow fragility. In practice, SPCs redefine sample handling in single-cell omics: not a bottleneck, but an enabling layer for experiments that need multiple steps at scale.”

— Emilis Gegevičius, Representative, Atrandi Biosciences (Business Wire)

What’s next

Atrandi will showcase its SPC technology and Phyx platform at booth #1443 during the SLAS2026 conference.

The takeaway

Atrandi's innovations in single-cell analysis workflows could enable researchers to tackle more complex, multi-step experiments without sacrificing critical data on individual cells, opening up new possibilities in fields like genomics, cancer research, and microbiology.